Further research is needed to establish the full range of neurological disorders relating to abnormal GluA2 expression and conductance, and to establish whether drugs targeting AMPARs, such as AMPAkines, would ameliorate clinical outcomes. The gene discussed is GRIA2; the disease is nervous system disorder.